Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin + sintilimab first-line phase II study in metastatic biliary tract cancer
ChiCTR2000033296Phase 2Recruiting
- Sponsor
- National Center for Biotechnology
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, gemcitabine and cisplatin in biliary cancer, sponsored by National Center for Biotechnology. Primary endpoint: 6-month progression-free survival rate. Started Jun 2020; status: recruiting.
02
Drugs
sintilimabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2000033296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033296.